The report portrays how GSK’s financial interests have – and will likely continue to – set back progress against the world’s deadliest infectious disease lays bare just how egregiously large pharmaceutical companies bilk the global public, and makes an urgent case for government and philanthropic funders to take action and demand better.

The decision is intended to assure current and future generic manufacturers that they may manufacture and sell generic versions of SIRTURO® without a concern that the Company will enforce its bedaquiline patents, provided the generic versions of SIRTURO® are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries.

Unitaid calls on Johnson & Johnson to drop secondary patents for the drug-resistant TB medicine bedaquiline, and to make negotiated rates with the Stop TB Partnership’s Global Drug Facility available to all countries, regardless of how they purchase drugs.

World leaders at the UN High-Level Meeting on TB have approved a Political Declaration with ambitious new targets for the next five years to advance the global efforts towards ending the TB epidemic.

USAID and PEPFAR announce that they have secured a 30% price reduction on the TB preventive treatment regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.

Ukraine, Belarus, Azerbaijan and Moldova demand that Johnson & Johnson take urgent action to improve equitable access to bedaquiline in all countries with a high burden of TB.

A sobering new analysis from Treatment Action Group shows that governments failed to meet previous commitments to fund TB research.

Ahead of the UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Global Fund, Stop TB Partnership and USAID announce new collaboration with Danaher to reduce price and increase access to Cepheid’s TB test. Five million additional tests can be procured with this lower price.

Results in the fight against HIV, TB and malaria exceed pre-COVID-19 numbers; yet colliding crises keep the world way off track to achieve 2030 targets.